Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    Obesity Leading Risk Factor of Left Atrial Enlargement During Aging - (DGNews)
    TopAbstracts in Hypertension 11/25/2009 - (DGNews)
    Team-Based Care Involving a Pharmacist Improves Blood Pressure Control - (DGNews)
    Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study - (BMJ)
    TopAbstracts in Hypertension 11/18/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • State of the Art in Pulmonary Arterial Hypertension
    • Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment
      Treating Coronary Artery Disease in Vulnerable Adults
      Thrombotic Thrombocytopenic Purpura: The Masquerader

      Webcasts/CME archive

       Recent cases - Hypertension
        A Woman with Swollen Fingers and New-Onset Hypertension and Renal Failure
        Hypertension
        Medical Management of a Pregnancy Woman with Moderate Renal Insufficiency and Superimposed Preclampsia
        Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Amlodipine Besylate/Benazepril HCl Combination Works Best for Lowering Blood Pressure: Presented at ACCP

        By Mike Fillon

        TAMPA, FL -- October 12, 2003 -- The combination of amlodipine besylate/benazepril hydrochloride (AML/BZP) is effective and well tolerated for first-line treatment of patients with severe systolic hypertension, according to results reported here on September 23rd at the 32nd Annual Meeting of the American College of Clinical Pharmacology.

        The 7th report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7) recommended initial combination therapy for patients whose blood pressure (BP) is at least 20/10 mm Hg above goal levels. Patients with State 2 hypertension, by definition, meet the JNC-7 recommendation for initiating combination antihypertensive therapy.

        This 12-week, randomised, multicentre, double-blind, parallel-group study was designed to compare the efficacy and safety of initial antihypertensive therapy using the fixed-dose combination of AML/BZP against that of AML alone in subjects with Stage 2 hypertension. The study included 364 subjects who were treated at 52 sites in the United States.

        After a 72-hour wash-out period, eligible subjects were randomised to dose level 1 (AML/BZP 5/20 mg or AML 10 mg). After 2 weeks on dose level 1, subjects who did reach the target blood pressure of 130/85 mm Hg or less were titrated to dose level 2 (AML/BZP 10/20 mg or AML 10 mg). Subjects who achieved the target level at Week 2 remained at dose level 1. If, at any subsequent visit, a subject's blood pressure level was less than 130/85 mm Hg, the dose was titrated to dose level 2. Downward dose adjustment to the previous dose level was not permitted.

        Hydrochlorothiazide 12.5 mg was added only in subjects who were on dose level 2 for at least 3 weeks and had systolic blood pressure levels between 180 mm Hg and 210 mm Hg, and/or the diastolic levels between 110 mm Hg and 120 mm Hg.

        At any time during the study, any subject with a systolic measurement greater than 210 mm Hg and/or diastolic level greater than 120 mm Hg was discontinued from the study.

        The researchers found that the fixed-dose combination of AML/BZP provided significantly greater efficacy and better tolerability compared with AML monotherapy in the initial treatment of subjects with State 2 hypertension. Also, the combination therapy resulted in maximum benefit in subjects with the highest blood pressure levels at baseline.

        "Recent data indicate [that] fixed-dose combination therapy with amlodipine besylate/benazepril HCl may better equip hypertensive patients to reach their BP goal more quickly than conventional combination therapy," said researcher Oliseyenum Nwose, Novartis Pharmaceuticals, Corp., East Hanover, New Jersey, United States, adding, "it offers comparable or improved BP control and tolerability compared to higher doses of monotherapy."

        Nwose also said that fixed-dose combination therapy may enhance medication adherence by use of a single capsule once-daily. "Because of these potential advantages, the use of combination antihypertensive therapy as initial treatment may be recommended, particularly in patients with target-organ damage or more severe initial levels of hypertension," he concluded.


        [Study Title: Therapy with Amlodipine Besylate/Benazepril HCl Provides Superior Control in Patients With Severe Systolic Hypertension. Abstract 84]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send